logo
The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know

The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know

Yahoo03-06-2025
The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know originally appeared on Parade.
You'd be surprised just how contentious a conversation about bagels can get. Sure, they might seem innocuous and like a relatively safe topic of discussion, but if you get the right people in the room, things can go south pretty quickly. Born and raised New Yorkers know a thing or two about where to get the best bagels and you better not even think about scooping out the insides like they do in LA. There are even rules about slicing, and according to some people the water in Jersey makes their bagels the best on the planet. Told you it was a minefield.
😋😋SIGN UP to get delicious recipes, handy kitchen hacks & more in our daily Pop Kitchen newsletter🍳🍔
Regardless of how you like your bagel—toasted, schmeared with cream cheese, buttered, or topped with lox—there's no denying that it's one of the greatest grab-and-go breakfasts known to mankind. It's filling and satiating leaving and can easily go from sweet to savory without skipping a beat. No matter what side of the bagel spectrum you fall on, we can all agree, life's sweeter with one in hand.The only thing that could possibly make us put the carby wonders down for good is if, by some chance, the unassuming doughy breakfast companion turned out to be hazardous to our health and the health of those around us. Unfortunately, in the case of Utah-based bagel company New Grains Gluten Free Bakery, it looks like that just might be the case. According to a recent filing by the FDA, the recall was issued due to the undeclared presence of eggs in four varieties of gluten-free bagels—cinnamon raisin, plain, blueberry, and multigrain.
Approximately 100 units of each type were affected by the recall. The recall is listed as Class I, the highest threat level, due to the potential for serious and life-threatening allergic reactions if consumed by someone with an egg allergy. In addition to the bagels, the brand also included artisan white bread, multigrain bread, sourdough, and cinnamon raisin bread in the recall due to the same labeling issue.
The products were distributed between April 4 and 21 under lot numbers 90-107 and were packaged in clear, vacuum-sealed plastic bags. A total of 250 units of each product were distributed to retail locations in Utah, so it seems that the recall is relatively insulated for now. While there have been no reported injuries or illnesses, it's best to avoid consumption if you happen to have purchased one of the affected products. Of course, yours truly isn't allergic to eggs, so I'll make sure to eat one for the both of us bestie.The FDA Just Upgraded a Recall On This Popular Breakfast Item To The Highest Level—Here's What to Know first appeared on Parade on Jun 3, 2025
This story was originally reported by Parade on Jun 3, 2025, where it first appeared.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Crinetics' treatment of CAH granted FDA orphan designation
Crinetics' treatment of CAH granted FDA orphan designation

Business Insider

time2 hours ago

  • Business Insider

Crinetics' treatment of CAH granted FDA orphan designation

Crinetics (CRNX)' treatment of congenital adrenal hyperplasia, generic name atumelnant, was granted FDA orphan designation, according to a post to the agency's site. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation
Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation

Business Insider

time2 hours ago

  • Business Insider

Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation

Keros Therapeutics (KROS)' treatment of Duchenne muscular dystrophy was granted FDA orphan designation, according to a post to the agency's site. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Regenxbio announces FDA review extension for RGX-121 BLA
Regenxbio announces FDA review extension for RGX-121 BLA

Business Insider

time4 hours ago

  • Business Insider

Regenxbio announces FDA review extension for RGX-121 BLA

Regenxbio (RGNX) announced that the U.S. Food and Drug Administration extended its review timeline of the Biologics License Application for clemidsogene lanparvovec for the treatment of Mucopolysaccharidosis II, also known as Hunter syndrome. The Prescription Drug User Fee Act goal date has been extended from November 9, 2025 to February 8, 2026. The extension follows the company's submission of longer-term clinical data for all patients in the pivotal study of RGX-121 in response to an FDA information request. These positive 12-month clinical data are consistent with biomarker and neurodevelopmental data previously submitted on the same patients in the BLA and will be presented during the International Congress of Inborn Errors of Metabolism in September 2025. In August 2025, the FDA completed a pre-license inspection and bioresearch monitoring information inspection for the RGX-121 BLA with no observations. No safety-related concerns have been raised by the FDA during the BLA review. 'Boys with this rare, devastating disease have no treatment options to address neurodevelopmental decline, and the Hunter syndrome community is in urgent need for a therapeutic option with the potential to improve these patients' lives,' said Curran M. Simpson, President and Chief Executive Officer of REGENXBIO. 'We promptly provided the FDA with the information requested and expect the commercial launch plans remain on track.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store